Encompass Health Corp (EHC)vsNovo Nordisk A/S (NVO)
EHC
Encompass Health Corp
$106.10
-0.98%
HEALTHCARE · Cap: $10.63B
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 5304% more annual revenue ($327.80B vs $6.07B). NVO leads profitability with a 37.2% profit margin vs 10.0%. EHC appears more attractively valued with a PEG of 0.41. EHC earns a higher WallStSmart Score of 75/100 (B+).
EHC
Strong Buy75
out of 100
Grade: B+
NVO
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+24.9%
Fair Value
$150.95
Current Price
$106.10
$44.85 discount
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 25 in profit
Earnings expanding 30.3% YoY
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Areas to Watch
No major concerns identified
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EHC
The strongest argument for EHC centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : EHC
No major red flags identified for EHC, but monitor valuation.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
EHC profiles as a value stock while NVO is a growth play — different risk/reward profiles.
EHC carries more volatility with a beta of 0.58 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
EHC scores higher overall (75/100 vs 74/100). Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Encompass Health Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Encompass Health Corporation offers in-home and post-acute health care services in the United States. The company is headquartered in Birmingham, Alabama.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?